Top

Published in:

01-03-2018

Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)

Authors: Rohit Moudgil, Parag A. Parekh

Published in: Heart Failure Reviews | Issue 2/2018

Abstract

Biomarkers are at the cornerstone of preventive measures and contribute to the screening process. More recently, biomarkers have been used to gauge the biological response to the employed therapies. Since it is ubiquitously used to detect subclinical disease process, biomarkers also have found its place in cancer therapy related cardiac dysfunction (CTRCD). The aim of this review is to comprehensively present up-to-date knowledge of biomarkers in CTRCD and highlight some of the future biomedical technologies that may strengthen the screening process, and/or provide new insight in pathological mechanisms behind CTRCD.

(1957) Chronic illness in the United States: Volume I. Prevention of chronic illness. Harvard University, Cambridge

Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. World Health Organization (WHO), Geneva

Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115(8):949–952. https://doi.org/10.1161/CIRCULATIONAHA.106.683110 CrossRefPubMed

Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358(20):2148–2159. https://doi.org/10.1056/NEJMra0800239 CrossRefPubMed

Germanakis I, Anagnostatou N, Kalmanti M (2008) Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 51(3):327–333. https://doi.org/10.1002/pbc.21633 CrossRefPubMed

Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J (2008) The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 25(7):655–664. https://doi.org/10.1080/08880010802244001 CrossRefPubMed

Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36(2):517–522. https://doi.org/10.1016/S0735-1097(00)00748-8 CrossRefPubMed

Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22):2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC CrossRefPubMed

Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, Albrile F, Bobbio M, Merlano M (2011) Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 148(2):194–198. https://doi.org/10.1016/j.ijcard.2009.09.564 CrossRefPubMed

10.

Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95(7):1592–1600. https://doi.org/10.1002/cncr.10854 CrossRefPubMed

11.

Dodos F, Halbsguth T, Erdmann E, Hoppe UC (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97(5):318–326. https://doi.org/10.1007/s00392-007-0633-6 CrossRefPubMed

12.

Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M (2004) Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 42(3):220–224. https://doi.org/10.1002/pbc.10368 CrossRefPubMed

13.

Koseoglu V, Berberoglu S, Karademir S et al (2005) Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin? Turk J Pediatr 47(1):17–22PubMed

14.

Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57(22):2263–2270. https://doi.org/10.1016/j.jacc.2010.11.063 CrossRefPubMed

15.

Goel S, Simes RJ, Beith JM (2011) Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia Pac J Clin Oncol 7(3):276–280. https://doi.org/10.1111/j.1743-7563.2011.01422.x CrossRefPubMed

16.

Stachowiak P, Kornacewicz-Jach Z, Safranow K (2014) Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy. Arch Med Sci 10(5):1007–1018. https://doi.org/10.5114/aoms.2013.34987 CrossRefPubMed

17.

Institute. NC. Common Terminology Criteria for Adverse Events v.3.0and v.4.03 (CTCAE). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

18.

Broeyer FJ, Osanto S, Ritsema van Eck HJ et al (2008) Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol 134(9):961–968. https://doi.org/10.1007/s00432-008-0372-8 CrossRefPubMedPubMedCentral

19.

Lee HS, Son CB, Shin SH, Kim YS (2008) Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat 40(3):121–126. https://doi.org/10.4143/crt.2008.40.3.121 CrossRefPubMedPubMedCentral

20.

Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136(2):362–363. https://doi.org/10.1053/hj.1998.v136.89908 CrossRefPubMed

21.

Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51(8):1405–1410. https://doi.org/10.1373/clinchem.2005.050153 CrossRefPubMed

22.

Skovgaard D, Hasbak P, Kjaer A (2014) BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS One 9(5):e96736. https://doi.org/10.1371/journal.pone.0096736 CrossRefPubMedPubMedCentral

23.

Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S, Matsuda T (2000) Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104(4):158–163. https://doi.org/10.1159/000046508 CrossRefPubMed

24.

Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DNJ (2000) Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 26(3):309–313. https://doi.org/10.1038/sj.bmt.1702507 CrossRefPubMed

25.

Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J (2002) Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251(3):228–234. https://doi.org/10.1046/j.1365-2796.2002.00951.x CrossRefPubMed

26.

Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7(1):87–93. https://doi.org/10.1016/j.ejheart.2004.03.009 CrossRefPubMed

27.

Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, de Vries EGE, Sleijfer DT, van der Graaf WTA (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19(10):2746–2753. https://doi.org/10.1200/JCO.2001.19.10.2746 CrossRefPubMed

28.

Cil T, Kaplan AM, Altintas A, Akin AM, Alan S, Isikdogan A (2009) Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig 29(2):131–137. https://doi.org/10.2165/0044011-200929020-00007 CrossRefPubMed

29.

Tanindi A, Demirci U, Tacoy G, Buyukberber S, Alsancak Y, Coskun U, Yalcin R, Benekli M (2011) Assessment of right ventricular functions during cancer chemotherapy. Eur J Echocardiogr 12(11):834–840. https://doi.org/10.1093/ejechocard/jer142 CrossRefPubMed

30.

Ekstein S, Nir A, Rein AJ et al (2007) N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 29(7):440–444. https://doi.org/10.1097/MPH.0b013e3180640d42 CrossRefPubMed

31.

Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AHB, Goldberg LR, Jessup M, Cappola TP (2012) Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 5(2):183–190. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965020 CrossRefPubMedPubMedCentral

32.

Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63(8):809–816. https://doi.org/10.1016/j.jacc.2013.10.061 CrossRefPubMed

33.

Sun F, Qi X, Geng C, Li X (2015) Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci 349(5):406–412. https://doi.org/10.1097/MAJ.0000000000000432 CrossRefPubMed

34.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596–603. https://doi.org/10.1161/CIRCIMAGING.112.973321 CrossRefPubMedPubMedCentral

35.

Feng YY, Yang ZJ (2015) Clinical application of the heart rate deceleration capacity test to predict Epirubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 66(4):371–375. https://doi.org/10.1097/FJC.0000000000000289 CrossRefPubMedPubMedCentral

36.

Shortt CR, Worster A, Hill SA, Kavsak PA (2013) Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. Clin Chim Acta 419:39–41. https://doi.org/10.1016/j.cca.2013.01.008 CrossRefPubMed

37.

Horacek JM, Tichy M, Jebavy L, Ulrychova M, Pudil R (2007) Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation. Ann Oncol 18(12):2041. https://doi.org/10.1093/annonc/mdm499 CrossRefPubMed

38.

Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361(9):858–867. https://doi.org/10.1056/NEJMoa0900428 CrossRefPubMed

39.

Tang WH, Francis GS, Morrow DA et al (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116(5):e99–109. https://doi.org/10.1161/CIRCULATIONAHA.107.185267 CrossRefPubMed

40.

Enroth S, Enroth SB, Johansson A, Gyllensten U (2015) Protein profiling reveals consequences of lifestyle choices on predicted biological aging. Sci Rep 5(1):17282. https://doi.org/10.1038/srep17282 CrossRefPubMedPubMedCentral

41.

Martin JA, Phillips JA, Parekh P, Sefah K, Tan W (2011) Capturing cancer cells using aptamer-immobilized square capillary channels. Mol BioSyst 7(5):1720–1727. https://doi.org/10.1039/c0mb00311e CrossRefPubMed

42.

Bayrac AT, Sefah K, Parekh P, Bayrac C, Gulbakan B, Oktem HA, Tan W (2011) In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci 2(3):175–181. https://doi.org/10.1021/cn100114k CrossRefPubMedPubMedCentral

43.

Ahmad KM, Oh SS, Kim S, McClellen FM, Xiao Y, Soh HT (2011) Probing the limits of aptamer affinity with a microfluidic SELEX platform. PLoS One 6(11):e27051. https://doi.org/10.1371/journal.pone.0027051 CrossRefPubMedPubMedCentral

44.

Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45(9):1628–1650PubMed

45.

Giannitsis E, Mueller-Hennessen M, Katus HA (2017) Aptamer-based proteomic profiling for prognostication in pulmonary arterial hypertension. Lancet Respir Med 5(9):671–672. https://doi.org/10.1016/S2213-2600(17)30209-6 CrossRefPubMed

46.

Cho EJ, Collett JR, Szafranska AE, Ellington AD (2006) Optimization of aptamer microarray technology for multiple protein targets. Anal Chim Acta 564(1):82–90. https://doi.org/10.1016/j.aca.2005.12.038 CrossRefPubMed

47.

Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs JSR, Condliffe R, Elliot CA, Kiely DG, Simonneau G, Montani D, Sitbon O, Gall H, Schermuly RT, Ghofrani HA, Lawrie A, Humbert M, Wilkins MR (2017) Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med 5(9):717–726. https://doi.org/10.1016/S2213-2600(17)30161-3 CrossRefPubMedPubMedCentral

48.

Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O’Sullivan JF, Keshishian H, Farrell LA, Fifer MA, Vasan RS, Sabatine MS, Larson MG, Carr SA, Wang TJ, Gerszten RE (2016) Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. Circulation 134(4):270–285. https://doi.org/10.1161/CIRCULATIONAHA.116.021803 CrossRefPubMedPubMedCentral

49.

Smith JG, Gerszten RE (2017) Emerging affinity-based proteomic technologies for large-scale plasma profiling in cardiovascular disease. Circulation 135(17):1651–1664. https://doi.org/10.1161/CIRCULATIONAHA.116.025446 CrossRefPubMed

50.

Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845–856. https://doi.org/10.1038/nrc1739 CrossRefPubMed

Title: Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
Authors: Rohit Moudgil
Parag A. Parekh
Publication date: 01-03-2018
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2018
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9675-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review

Imaging technologies for cardiac fiber and heart failure: a review

Temporary assist device support for the right ventricle: pre-implant and post-implant challenges

Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison

Transplantation in patients with iron overload: is there a place for magnetic resonance imaging?

Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page